NZ744036A - Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof - Google Patents

Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof Download PDF

Info

Publication number
NZ744036A
NZ744036A NZ744036A NZ74403614A NZ744036A NZ 744036 A NZ744036 A NZ 744036A NZ 744036 A NZ744036 A NZ 744036A NZ 74403614 A NZ74403614 A NZ 74403614A NZ 744036 A NZ744036 A NZ 744036A
Authority
NZ
New Zealand
Prior art keywords
patient
treating
bardoxolone methyl
identified
analogs
Prior art date
Application number
NZ744036A
Other languages
English (en)
Inventor
Melanie Pei-Heng Chin
Colin J Meyer
Original Assignee
Reata Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals Inc filed Critical Reata Pharmaceuticals Inc
Priority to NZ756256A priority Critical patent/NZ756256A/en
Publication of NZ744036A publication Critical patent/NZ744036A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
NZ744036A 2013-08-23 2014-08-22 Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof NZ744036A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ756256A NZ756256A (en) 2013-08-23 2014-08-22 Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361869527P 2013-08-23 2013-08-23
NZ630951A NZ630951A (en) 2013-08-23 2014-08-22 Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof

Publications (1)

Publication Number Publication Date
NZ744036A true NZ744036A (en) 2020-09-25

Family

ID=51794949

Family Applications (4)

Application Number Title Priority Date Filing Date
NZ744036A NZ744036A (en) 2013-08-23 2014-08-22 Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
NZ756256A NZ756256A (en) 2013-08-23 2014-08-22 Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
NZ774222A NZ774222A (en) 2013-08-23 2014-08-22 Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
NZ630951A NZ630951A (en) 2013-08-23 2014-08-22 Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof

Family Applications After (3)

Application Number Title Priority Date Filing Date
NZ756256A NZ756256A (en) 2013-08-23 2014-08-22 Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
NZ774222A NZ774222A (en) 2013-08-23 2014-08-22 Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
NZ630951A NZ630951A (en) 2013-08-23 2014-08-22 Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof

Country Status (18)

Country Link
US (3) US20150080465A1 (https=)
EP (2) EP4736949A2 (https=)
JP (3) JP6564372B2 (https=)
KR (1) KR102322057B1 (https=)
CN (2) CN105517554B (https=)
AU (2) AU2014308600B2 (https=)
BR (1) BR112016003454B1 (https=)
CA (1) CA2921386A1 (https=)
CL (1) CL2016000405A1 (https=)
EA (1) EA201690456A1 (https=)
IL (3) IL285832B2 (https=)
MX (2) MX380589B (https=)
MY (2) MY198522A (https=)
NZ (4) NZ744036A (https=)
PH (1) PH12016500358B1 (https=)
SG (2) SG11201601202WA (https=)
TW (2) TWI716341B (https=)
WO (1) WO2015027206A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0907423A2 (pt) 2008-01-11 2020-10-27 Reata Pharmaceuticals, Inc. composto triterpenoide sintético para uso em um método de melhoria da função renal em um indivíduo, e uso do referido composto
JP5529851B2 (ja) 2008-04-18 2014-06-25 リアタ ファーマシューティカルズ インコーポレイテッド 抗酸化炎症モジュレーター：ｃ−１７においてアミノ改変およびその他の改変を加えたオレアノール酸誘導体
WO2009146218A2 (en) 2008-04-18 2009-12-03 Reata Pharmaceuticals, Inc. Compounds including an anti-inflammatory pharmacore and methods of use
CN103596929B (zh) 2010-12-17 2016-10-19 里亚塔医药公司 作为抗氧化发炎调节剂的吡唑及嘧啶三环烯酮
TWI623548B (zh) 2012-04-27 2018-05-11 瑞塔醫藥有限責任公司 齊墩果酸（ｂａｒｄｏｘｏｌｏｎｅ ｍｅｔｈｙｌ）之２，２-二氟基丙醯胺衍生物、多晶型及其使用方法
WO2013188818A1 (en) 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
WO2014040073A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
JP6243428B2 (ja) 2012-09-10 2017-12-06 リアタ ファーマシューティカルズ インコーポレイテッド オレアノール酸のｃ１７−アルカンジイルおよびアルケンジイル誘導体ならびにその使用方法
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
AR096046A1 (es) 2013-04-24 2015-12-02 Abbvie Inc Derivados de 2,2-difluoropropanamida de metil bardoxolona, formas polimórficas y métodos de uso
EP4736949A2 (en) * 2013-08-23 2026-05-06 Reata Pharmaceuticals Holdings, LLC Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
EP3256451B1 (en) 2015-02-12 2021-10-20 Reata Pharmaceuticals, Inc. Imidazolyl tricyclic enones as antioxidant inflammation modulators
JP6871919B2 (ja) 2015-06-16 2021-05-19 ナノファギックス エルエルシー 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法
JP7074674B2 (ja) 2015-09-23 2022-05-24 リアタ ファーマシューティカルズ インコーポレイテッド Ｉｌ－１７の阻害及び他の使用のためのｃ４修飾オレアノール酸誘導体
CN110198718B (zh) 2016-11-08 2023-01-10 里亚塔医药控股有限责任公司 使用甲基巴多索隆或其类似物治疗阿尔波特综合征的方法
CN106632574B (zh) * 2016-12-07 2018-05-29 广东天键生物科技有限公司 一种化合物、其制备方法及用途
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
WO2018200692A1 (en) * 2017-04-26 2018-11-01 The Trustees Of The University Of Pennsylvania Methods and systems for virtual and augmented reality training for responding to emergency conditions
US11993574B2 (en) 2018-06-15 2024-05-28 Reata Pharmaceuticals, Inc Pyrazole and imidazole compounds for inhibition of IL-17 and RORgamma
US12060340B2 (en) 2018-06-20 2024-08-13 Reata Pharmaceuticals, Inc Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith
MX2021003643A (es) * 2018-09-28 2021-08-19 Sichuan Haisco Pharmaceutical Co Ltd Derivados de terpenoides y usos de los mismos.
WO2020080482A1 (ja) * 2018-10-17 2020-04-23 株式会社 資生堂 血液中のシスタチンｃ量に基づく腎機能検査結果の妥当性を検定する方法
EP3999522B1 (en) * 2019-07-19 2025-09-03 Reata Pharmaceuticals, Inc. C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof
WO2021104391A1 (zh) * 2019-11-27 2021-06-03 鲁南制药集团股份有限公司 一种齐墩果烷苯丙烯酰胺衍生物及其制备方法和用途
US11969424B2 (en) 2019-12-16 2024-04-30 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
CA3164676A1 (en) * 2019-12-23 2021-07-01 Toray Industries, Inc. Drug for preventing dialysis shift or renal death
WO2021202720A1 (en) * 2020-04-01 2021-10-07 Fronthera U.S. Pharmaceuticals Llc Use of triterpenoid nrf2 inhibitors
BR112022022599A2 (pt) * 2020-05-09 2023-03-21 Reata Pharmaceuticals Holdings Llc Métodos de tratamento de covid-19 usando bardoxolona metil ou análogos da mesma
CN111704647B (zh) * 2020-06-15 2021-10-22 中国人民解放军海军军医大学 一类三萜类衍生物及其作为程序性细胞坏死抑制剂的用途
AU2021397631A1 (en) 2020-12-11 2023-07-20 Reata Pharmaceuticals Holdings, LLC Synthetic triterpenoids for use in therapy
US12064409B2 (en) 2021-06-22 2024-08-20 Vanderbilt University Action of L-citrulline to prevent or treat endothelial dysfunction
CN114097807B (zh) * 2021-11-25 2023-05-05 兰州大学 巴多索隆类化合物在抗农业病原真菌中的用途
CN116509874A (zh) * 2023-02-01 2023-08-01 潍坊医学院附属医院 甲基巴多索隆在制备改善病毒性心肌炎或病毒性心肌损伤的药物中的用途
CN117964678A (zh) * 2024-01-29 2024-05-03 烟台大学 C17位杂芳族羰基修饰的齐墩果烷三萜衍生物及其制备方法和用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
CA2107894C (en) 1991-04-10 2003-10-14 Kenneth F. Buechler Crosstalk inhibitors and their uses
EP0579767B1 (en) 1991-04-11 2000-08-23 Biosite Diagnostics Inc. Novel conjugates and assays for simultaneous detection of multiple ligands
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US6019944A (en) 1992-05-21 2000-02-01 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
GB9212302D0 (en) 1992-06-10 1992-07-22 Applied Research Systems Method for improving measurement precision in evanescent wave optical biosensor assays
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6025395A (en) 1994-04-15 2000-02-15 Duke University Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US7176237B2 (en) 2002-01-15 2007-02-13 The Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
PE20040468A1 (es) * 2002-05-17 2004-09-14 Novartis Ag Combinacion de compuestos organicos
US20040102361A1 (en) * 2002-11-27 2004-05-27 Frederic Bodin Pharmaceutical composition for the treatment of pulmonary arterial hypertension
MXPA06012279A (es) * 2004-04-23 2007-01-31 Celgene Corp Metodos de uso y composiciones que comprenden moduladores de pde4 para el tratamiento y manejo de la hipertension pulmonar.
EP2094651A1 (en) 2006-11-17 2009-09-02 Trustees Of Dartmouth College Synthesis and biological activities of new tricyclic-bis-enones (tbes)
ES2401741T3 (es) 2007-05-08 2013-04-24 Abbott Laboratories Ensayo de péptido natriurético de tipo B humano que tiene una reducida reactividad cruzada con otras formas péptidicas
US8088824B2 (en) 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
BRPI0907423A2 (pt) * 2008-01-11 2020-10-27 Reata Pharmaceuticals, Inc. composto triterpenoide sintético para uso em um método de melhoria da função renal em um indivíduo, e uso do referido composto
US8071632B2 (en) 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
KR101713140B1 (ko) * 2008-04-18 2017-03-08 리타 파마슈티컬스 잉크. Ｃ-환에서 포화된 산화방지성 염증 조절제 올레아놀산 유도체
JP5529851B2 (ja) 2008-04-18 2014-06-25 リアタ ファーマシューティカルズ インコーポレイテッド 抗酸化炎症モジュレーター：ｃ−１７においてアミノ改変およびその他の改変を加えたオレアノール酸誘導体
WO2009146218A2 (en) 2008-04-18 2009-12-03 Reata Pharmaceuticals, Inc. Compounds including an anti-inflammatory pharmacore and methods of use
MX2010011439A (es) 2008-04-18 2011-01-25 Reata Pharmaceuticals Inc Moduladores de inflamacion antioxidantes: derivados del acido oleanolico homologacion c-17.
SI2395979T1 (sl) 2009-02-13 2017-12-29 Reata Pharmaceuticals, Inc. Peroralni farmacevtski sestavki, ki vsebujejo amorfni CDDO-Me, z zapoznelim sproščanjem
DK2558105T3 (da) * 2010-04-12 2020-01-27 Reata Pharmaceuticals Inc Bardoxolonmethyl til behandling af fedme
EP4736949A2 (en) * 2013-08-23 2026-05-06 Reata Pharmaceuticals Holdings, LLC Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof

Also Published As

Publication number Publication date
IL285832B1 (en) 2023-09-01
JP6526306B2 (ja) 2019-06-05
TW202026003A (zh) 2020-07-16
TWI716341B (zh) 2021-01-21
JP2019131599A (ja) 2019-08-08
IL244171A0 (en) 2016-04-21
AU2014308600A1 (en) 2016-03-03
US20150080465A1 (en) 2015-03-19
JP6564372B2 (ja) 2019-08-21
EP4736949A2 (en) 2026-05-06
EP3035937A1 (en) 2016-06-29
CL2016000405A1 (es) 2017-02-24
CN105517554B (zh) 2021-01-15
JP2019048873A (ja) 2019-03-28
MX380589B (es) 2025-03-12
KR20160061994A (ko) 2016-06-01
IL285832B2 (en) 2024-01-01
AU2014308600B2 (en) 2020-03-05
CA2921386A1 (en) 2015-02-26
NZ756256A (en) 2021-07-30
IL272242B (en) 2021-09-30
SG11201601202WA (en) 2016-03-30
AU2020203510A1 (en) 2020-06-18
BR112016003454B1 (pt) 2023-02-14
CN105517554A (zh) 2016-04-20
WO2015027206A1 (en) 2015-02-26
NZ774222A (en) 2023-01-27
BR112016003454A2 (pt) 2017-08-01
MY198522A (en) 2023-09-04
IL285832A (en) 2021-09-30
EA201690456A1 (ru) 2016-06-30
WO2015027206A8 (en) 2015-06-11
PH12016500358B1 (en) 2023-08-16
US20190091194A1 (en) 2019-03-28
IL244171B (en) 2020-02-27
US20240115542A1 (en) 2024-04-11
MX2021002897A (es) 2021-06-08
PH12016500358A1 (en) 2016-05-16
HK1223015A1 (zh) 2017-07-21
MX2016002375A (es) 2016-12-20
CN112870202A (zh) 2021-06-01
SG10201906113RA (en) 2019-08-27
JP6701407B2 (ja) 2020-05-27
TWI717026B (zh) 2021-01-21
NZ630951A (en) 2018-09-28
AU2020203510B2 (en) 2023-05-11
IL272242A (en) 2020-02-27
KR102322057B1 (ko) 2021-11-05
EP3035937B1 (en) 2025-12-31
JP2016528300A (ja) 2016-09-15
MY205497A (en) 2024-10-23
TW201542211A (zh) 2015-11-16

Similar Documents

Publication Publication Date Title
NZ744036A (en) Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
MY194850A (en) (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors
PH12016501149A1 (en) Apoptosis signal-regulating kinase inhibitors
EA201500997A1 (ru) Терапевтические применения эмпаглифлозина
WO2014126944A3 (en) Inhibitors of the renal outer medullary potassium channel
IL256084B (en) Crystalline arginine salt of (Ar)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-4,3,2,1-tetrahydro-cyclopent[b]indol-3-yl)acetic acid (compound) 1) for use in disorders related to the sphingosine-1-phosphate-A receptor.
HRP20220978T1 (hr) Upotreba oksidiranih kolesterol sulfata (ocs) za liječenje disfunkcije bubrega
PH12015502275B1 (en) Therapuetic uses of empagliflozin
WO2015077540A3 (en) Compositions and methods for treating pulmonary hypertension
EA201690741A1 (ru) Составы (s)-3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона
EA201490941A1 (ru) Модуляторы mas рецептора, сопряженного с g-белком, и лечение связанных с ним расстройств
WO2015095097A3 (en) Inhibitors of the renal outer medullary potassium channel
MX2017000635A (es) Inhibidores del canal de potasio medular externo renal.
MA37455A1 (fr) Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique
EA201790905A1 (ru) Способ лечения состояний, связанных с рецептором pgi2
LT3972604T (lt) Brutono tirozino kinazės inhibitorius, skirtas naudoti lėtinės spontaninės dilgėlinės gydymui
FI3630164T3 (fi) Dulaglutidi kroonisen munuaissairauden hoitoon
PH12016500042A1 (en) Stabilized pharmaceutical dosage forms comprising atrasentan
MX2017000634A (es) Inhibidores del canal de potasio medularmente externo renal.
MX2016016491A (es) Derivados de o-alquil-bencilidenguanidina y uso terapeutico para el tratamiento de trastornos asociados con acumulacion de proteinas mal plegadas.
MX381526B (es) Agente para suprimir el progreso de o para mejorar la enfermedad renal crónica.
RU2016124538A (ru) Антагонисты гастрина для лечения и профилактики остеопороза
JP2016538295A5 (https=)
AR099416A1 (es) Terapia combinada para la hipertensión resistente
HK1224220A1 (zh) 治疗神经退化性失调的方法

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 22 AUG 2021 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD

Effective date: 20210429

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 AUG 2022 BY CPA GLOBAL

Effective date: 20210729

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 AUG 2023 BY CPA GLOBAL

Effective date: 20220804

ASS Change of ownership

Owner name: REATA PHARMACEUTICALS HOLDING, US

Effective date: 20220912

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 AUG 2024 BY CPA GLOBAL

Effective date: 20230727

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 AUG 2025 BY ANAQUA SERVICES

Effective date: 20240723

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 AUG 2026 BY ANAQUA SERVICES

Effective date: 20250724